GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Seasonal Allergic Rhinitis

Conditions

Seasonal Allergic Rhinitis

Trial Timeline

Dec 1, 2014 → Feb 1, 2015

NCT ID

NCT02318303

About GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)

GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID) is a phase 2 stage product being developed by Glenmark Pharmaceuticals for Seasonal Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02318303. Target conditions include Seasonal Allergic Rhinitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02318303	Phase 2	Completed	Dec 1, 2014	Feb 1, 2015	Seasonal Allergic Rhinitis

Competing Products

20 competing products in Seasonal Allergic Rhinitis

See all competitors

Product	Company	Stage	Hype Score
Bilastine + Desloratadine + Placebo	Yuhan	Phase 3	77
ASP4070 + Placebo	Astellas Pharma	Phase 2	52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placebo	Shionogi	Phase 2	52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + Placebo	Ono Pharmaceutical	Phase 2	52
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo	Sumitomo Pharma	Phase 3	77
80 mcg Ciclesonide + 160 mcg Ciclesonide + Placebo	Sumitomo Pharma	Phase 3	77
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + Placebo	Sumitomo Pharma	Phase 3	77
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal spray	Glenmark Pharmaceuticals	Phase 2	52
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placebo	Johnson & Johnson	Phase 1	33
Ciclesonide + Placebo	AstraZeneca	Phase 3	77
Ciclesonide + Placebo	AstraZeneca	Phase 3	77
Ciclesonide HFA + Ciclesonide HFA + Ciclesonide HFA + Placebo	AstraZeneca	Phase 2	52
budesonide + Placebo	AstraZeneca	Phase 2	52
Ciclesonide + Placebo	AstraZeneca	Phase 3	77
Ciclesonide Nasal Spray	AstraZeneca	Phase 3	77
Budesonide + Fluticasone propionate + Placebo	AstraZeneca	Phase 3	77
Ciclesonide + Ciclesonide Placebo	AstraZeneca	Phase 3	77
loratadine	Merck	Pre-clinical	23
MK0524	Merck	Phase 2	52
loratadine; montelukast	Merck	Phase 3	77

Other Products from Glenmark Pharmaceuticals

Nitric OxidePhase 3

Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerPhase 3

Diclofenac Sodium gel, 1% + Voltaren® Gel + PlaceboPhase 3

Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.)Phase 3

Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboPhase 3